Lecture 9/10 - Disorders of haemostasis Flashcards

1
Q

Four causes of defective haemostasis with abnormal bleeding

A
  • Abnormalities of the vessel wall (vascular system)
  • Thrombocytopenia
  • Disordered platelet function (thrombocytopathy)
  • Defective blood coagulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are vessel wall abnormalities characterised?

A

Characterized by easy bruising and purpura (bleeding into the skin or mucous membranes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are vascular and platelet bleeding disorders associated with?

A

Associated with bleeding from the mucous membranes and into the skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where is bleeding often located in Coagulation disorders?

A

Bleeding is often into joints or soft tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Vascular building disorders: what are the characteristics and what is the pathology?

A

Characteristics:
* Easy bruising
* Spontaneous bleeding from small vessels

Pathology:
* Abnormality in blood vessels
* Bleeding and other haemostasis tests usually normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hereditary haemorrhagic Telangiectasia: how many people are affected, is it a dominant or recessive illness, where are the defects in the genome, what are they symptoms, and what are the treatments?

A

Uncommon - approx. 1.2 million worldwide (equally between men and women)

Autosomal dominant

Defects in at least 3 genes but only 1 gene is the cause in any one family

Abnormally formed blood vessels: Arteriovenous malformations

Symptoms mild - severe:
* Telangiectases - dilated microvascular swellings, easy to rupture (90-95%: at least a few telangiectasias on the skin of the face and/or hands by middle age)
* nose, tongue and lips (90-95% nosebleeds by adulthood at varying frequencies)
* Nosebleeds and gastrointestinal blood loss.
* Chronic iron deficiency is frequent
* 20-25%: bleeding in the stomach or intestines, but rarely before 50 y.old.

Treatment: embolization, laser treatment and tranexamic acid (prevents fibrinolysis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acquired vascular defects: what causes them, and what can they be characterised as?

A

Wide variety of causes: incl. infections, drug reactions, trauma, old age and steroid use.

Vascular purpura can be categorized as such:

  • Purpura simplex - common benign disorder, in women of childbearing age.
  • Senile purpura - old age, due to the loss of skin elasticity and atrophy of vascular collagen, mainly on the forearms and hands
  • Infection-associated purpura - bacterial and viral infections, e.g. measles can cause purpura from vascular damage by the organism.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Thrombocytopenia: what is it and what are the three main causes of it?

A

Deficiency in platelet numbers (defined as a low platelet count with values less than 150 x 109/L)

3 main causes of thrombocytopenias:
* Failure of platelet production
* Increased destruction of platelets
* Sequestration (abnormal distribution) of platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Platelet production failure: what is it the most common cause of, what is it usually caused by, and how do we diagnose it?

A

Most common cause of thrombocytopenia

  • Usually part of bone marrow failure - aplastic anaemia/leukaemia (deficiency in blood cells produced)
  • drug/viral-induced toxicity

Clinical history, peripheral blood count, blood film, and bone marrow examination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Increased destruction of platelets: what is it usually caused by and what does it result in?

A

Autoimmune response - autoantibodies attach to platelet surface

Autoimmune (idiopathic) thrombocytopenia purpura (ITP) in two disease categories: chronic ITP and acute ITP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Chronic ITP: what are the general features, what causes it, and what happens to platelet lifespan?

A

Relatively common in young women 15-60 years old, often asymptomatic or have an insidious onset of bleeding?

Autoantibodies (mostly IgG) in plasma and on platelets which make them get destroyed by macrophages in the spleen and liver.

((((Antibodies: glycoprotein IIb/IIIa or Ib)))

Platelet lifespan considerably reduced: as little as a few hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acute ITP: general features, what causes it, and what two ways does it usually lead to?

A

Children under 10

The majority is abrupt following vaccination or viral episode as the IgG antibody attaches to the viral antigen and is absorbed onto the platelet surface, causing a dramatic fall in platelet count (may be less than 20 x 109/L)

  • Spontaneous remissions usual
  • The minority of cases develop chronic ITP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sequestrian of platelets: how many platelets are in the spleen normal and how many platelets are in the spleen when splenomegaly occurs?

A

Normally, the spleen contains ~30% of all platelets

Splenomegaly: up to 90% of platelets sequestered in the spleen - thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Thrombocytopathy: what is it, when is it diagnosed, and what is it caused by?

A

Disorders of Platelet Function

Considered when clinical signs and symptoms of thrombocytopenia but in the presence of a normal platelet count

Inherited and Acquired disorders:
* Inherited disorders - rare but capable of producing defects at each of the different phases of the platelet reaction (activation, adhesion, secretion, aggregations).
* Acquired disorders - much more common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Antiplatelet drugs (Aspirin): what do they do, what do they result in, and what is their effect of them?

A

Irreversibly inactivates the enzyme cyclooxygenase (COX), preventing the production of thromboxane A2 from arachidonic acid

Result: inhibition of platelet aggregation

Significantly extends the bleeding time which may cause haemorrhage in patients with thrombocytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Haematological malignancy: what does it do and what may it be caused by?

A

Causes platelets to function incorrectly

  • acute myeloid leukaemia
  • any myeloproliferative disorders and myeloma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Platelet disorder diagnosis

A
  • Initial blood count and blood film examination
  • Bone marrow biopsy - thrombocytopenic patients, ascertain failure of platelet production
  • Blood count: within normal limits - other tests performed to detect abnormal platelet function
  • Prolonged bleeding time detected - defect usually acquired and should be evident in clinical investigation
  • Patients with hereditary defects require further testing to define the specific abnormality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Haemophilia a

A

The most common hereditary clotting factor deficiency

Factor VIII deficiency

30-100 per million of a population

X-linked recessive disorder - all males with the defective gene suffer, sons of haemophiliac men are (usually) non-sufferers but their daughters will be carriers (or sufferers)

Can be spontaneously mutated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Clinical features of factor VIII level in bleeding severity: what are the symptoms and what are deaths mainly caused by?

A

Severity of bleeding is related to the factor VIII level

Clinical features of severe haemophilia:
* Bleeding into joints and less frequently muscles
* Knees, elbows and ankles are most commonly affected by bleeding
* The majority of bleeds require treatment
* Presenting symptoms: pain in affected areas

Intracranial bleeding: the main cause of death from the disease
High death rate: HIV-contaminating factor VIII observed in the USA and Europe in the last two decades

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Haemophilia b: what is it, what is it caused by, how many people suffer from it, how related is it to haemophilia a clinically, and how is it treated?

A

X-linked recessive bleeding disorder

Factor IX deficiency

Not as common as haemophilia a (15-20 per million of the population)

Clinically indistinguishable from haemophilia a
APTT prolonged, confirmed by factor IX clotting assay

Use of factor IX as a replacement

21
Q

Haemarthrosis

A

Bleed into elbow

22
Q

Diagnosis of haemophilia a

A
  • APTT (prolonged activated partial thromboplastin time)
  • Confirmed by a factor VIII clotting assay
  • Carrier detection and antenatal diagnosis by using DNA technology
  • Chorionic biopsies at 8-10 weeks of gestation provide DNA for analysis.
23
Q

The concentration of coagulation factor (%of normal) and its relation to bleeding episodes in haemophilia a sufferers

A

50-100% - none, same as healthy
25-50% - bleeding after severe trauma
5-25% - severe bleeding episodes after surgery, slight bleeding episodes after minor trauma
1-5% - Severe bleeding after slight trauma
<1% - Severe, frequent spontaneous bleeding episodes predominantly in joints and muscles

24
Q

Haemophilia a treatment

A

Factor VIII replacement after bleeding, usually recombinant factor VIII

When the disease is mild - 1-amino-8-D-arginine vasopressin (DDAVP) is used to mobilize factor VIII from endothelial cells

25
Q

VWD: what is it, how prevalent is it, and what is it caused by?

A

Von Willebrand’s disease

1 in 100 have it but have no symptoms
1 in 10,000 is clinically significant

Autosomal dominant gene - mutations in the VWF gene cause reduced platelet adhesion to damaged endothelium

26
Q

VWD: classification

A

Classification:
- Three types which depend on the electrophoretic analysis of VWF multimers:
* Types 1 and 3: partial reduction or nearly complete absence of VWF molecules and
* Type 2: abnormal form of the protein – functional abnormality

27
Q

VWD: diagnosis

A

Diagnosis:
* Prolonged APTT
* Reduced factor VIII clotting activity
* Reduced levels of VWF
* Impaired platelet aggregation

28
Q

VWD: clinical features and treatment

A
  • Variable bleeding extent, spontaneous bleeding usually confined to mucous membranes and skin
  • Surgery may result in severe bleeding

Treatment:
* DDVAP (Desmopressin):
- For those mild or moderately affected
- Increases both VWF and factor VIII
- most effective in type 1 VWD patients

  • Tranexamic acid: mild bleeding
29
Q

Acquired coagulation disorders

A

Usually multifactorial

Associated with varying assortments of platelet dysfunction and coagulation abnormalities including:
* Vitamin K deficiency
* Disseminated intravascular coagulation
* Liver disorders

30
Q

Thrombus

A

Platelets and fibrin forming colts in circulation, can develop in arteries or veins, with the incidence increasing in age

31
Q

Embolism

A

Cuased by the occlusion of a vessel by foreign material/blood cliot

This may cause a thrombus to occur

32
Q

Thromboembolism

A

Occlusion of a vessel by a blood clot which has moved from its starting position

When movement is to the lungs - pulmonary thromboembolism

33
Q

Thrombosis causes

A

Risk factors - differ for arterial and venous thrombosis

Thrombophilia - inherited or acquired disorders (genetically predisposed to thrombosis)

34
Q

Virchow’s triad

A

Outlines factors predisposing one to thrombus formation:
* Changes in blood flow (plane journey, sitting down etc)
* Changes in blood constituents (Hypercoagulability of the blood, i.e. caused by genetic deficiencies)

  • Changes within the walls of blood vessels - (vessel wall damage, i.e. caused by trauma, infection)
35
Q

Arterial thrombosis

A

Thrombus within an artery - rupture of atheroma

Two diseases can be classified under this category:
* Stroke
* Myocardial infarction

36
Q

Stroke

A
  • Disturbance in blood supply to the brain
  • Thrombotic stroke - thrombosis forms around atherosclerotic plaque with a gradual artery blockage
37
Q

Myocardial infarction

A
  • Caused by an infarct (tissue death to ischemia)
  • Often due to coronary artery obstruction
  • If diagnosed within 12 hours of the initial attack, thrombolytic therapy initiated
38
Q

Arterial thrombosis risk factors

A
  • Positive family history
  • Male
  • Cigarette smoking
  • Diabetes mellitus
  • Hypertension
  • Collagen vascular disease
  • ECG abnormalities
  • Elevated fibrinogen
  • Elevated factor VII
39
Q

Venous thrombosis/thromboembolism

A

Increased systemic coagulability and stasis

Deep vein thrombosis - most common in lower limbs

  • Swelling (often asymmetrical)
  • Pain, erythema
  • If part of DVT dislodges and forms an embolus, it can lodge itself in lung vasculature - PE
40
Q

Pulmonary embolism symptoms

A
  • Dyspnoea - not being able to breathe fast/deep enough
  • Tachypnoea - Rapid and shallow breathing
  • Pleuritic chest pain - sharp chest pain when inhaling deeply
41
Q

Venous thrombosis hereditary risk factors

A

Factor V Leiden
Antithrombin III deficiency
Prothrombin G20210A variant
Protein/ protein S deficiency

42
Q

Venous thrombosis hereditary/acquired risk factors

A

Raised plasma levels of FVII, VIII, IX, XI, or fibrinogen
Lupus anticoagulant
Oral contraceptive / HRT
Malignancy

43
Q

Venous thrombosis stasis risk factors

A

Stroke
Cardiac failure
Prolonged immobility

44
Q

Venous thrombosis risk factors - unknown factors

A

Age, Obesity, Sepsis

45
Q

Factor V Leiden: what does it cause, what is it, what difference do heterozygote and homozygote sufferers have, what is the incidence in those with venous thrombosis, and what does the mutation act as?

A

Inherited thrombophilia

Activated protein C resistance (x10 resistance to cleavage)

Autosomal dominant, the most common cause of increased venous thrombosis
5% incidence rate in Caucasians in the UK
A single point mutation (R-Q) causes 90% of cases

Heterozygotes: 7-fold increased risk of thrombosis
Homozygotes: 50-fold increased risk

Incidence of FV Leiden in patients with venous thrombosis is ~20-40%

Mutation acts as a co-factor in some hypercoagulable states: e.g. oral contraceptive pill and pregnancy, surgery and immobility

46
Q

Acquired thrombophilia - risk factors

A
  • Prolonged immobilisation of patient - venous stasis
  • Disseminated cancer - secretion of tumour substances that activate FX
  • Endothelial injury - smoking, hypercholesterolaemia, hypertension, infection
  • Alterations to blood flow: Atrial fibrillation
47
Q

Antithrombotic therapy

A

Two main classes of drug used:
Anticoagulants (heparin/warfarin) - prevent thrombosis

Thrombolytic agents - dissolve thrombus

48
Q

Thrombolytic agents

A

Must be used before anticoagulant

Mechanism of action - acts as plasminogen activators, converting plasminogen into plasmin which will then dissolve the fibrin of a blood clot

Commonly used agents are:
* Streptokinase (SK): activates free and fibrin-bound plasminogen to release plasmin
* Tissue plasminogen activator (tPA): has a high affinity for fibrin with specific lysis of thrombin